Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ:RYTM
Total Valuation
Rhythm Pharmaceuticals has a market cap or net worth of $6.53B. The enterprise value is $6.54B.
Market Cap$6.53B
Enterprise Value$6.54B
Share Statistics
Rhythm Pharmaceuticals has 66,736,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding66,736,050
Owned by Insiders0.68%
Owned by Institutions0.46%
Financial Efficiency
Rhythm Pharmaceuticals’s return on equity (ROE) is -1.58 and return on invested capital (ROIC) is -95.53%.
Return on Equity (ROE)-1.58
Return on Assets (ROA)-0.66
Return on Invested Capital (ROIC)-95.53%
Return on Capital Employed (ROCE)-0.96
Revenue Per Employee459.81K
Profits Per Employee-920.86K
Employee Count283
Asset Turnover0.33
Inventory Turnover0.71
Valuation Ratios
The current PE Ratio of Rhythm Pharmaceuticals is ―. Rhythm Pharmaceuticals’s PEG ratio is -0.37.
PE Ratio―
PS Ratio26.24
PB Ratio20.75
Price to Fair Value20.75
Price to FCF-29.98
Price to Operating Cash Flow-59.14
PEG Ratio-0.37
Income Statement
In the last 12 months, Rhythm Pharmaceuticals had revenue of 130.13M and earned -260.60M in profits. Earnings per share was -4.34.
Revenue130.13M
Gross Profit116.76M
Operating Income-265.50M
Pretax Income-260.26M
Net Income-260.60M
EBITDA-238.09M
Earnings Per Share (EPS)-4.34
Cash Flow
In the last 12 months, operating cash flow was -109.13M and capital expenditures 0.00, giving a free cash flow of -109.13M billion.
Operating Cash Flow-109.13M
Free Cash Flow-109.13M
Free Cash Flow per Share-1.64
Dividends & Yields
Rhythm Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.81
52-Week Price Change76.79%
50-Day Moving Average102.50
200-Day Moving Average77.17
Relative Strength Index (RSI)43.49
Average Volume (3m)614.20K
Important Dates
Rhythm Pharmaceuticals upcoming earnings date is Mar 4, 2026, TBA (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateMar 4, 2026
Ex-Dividend Date―
Financial Position
Rhythm Pharmaceuticals as a current ratio of 3.24, with Debt / Equity ratio of 101.47%
Current Ratio3.24
Quick Ratio3.08
Debt to Market Cap0.03
Net Debt to EBITDA-0.70
Interest Coverage Ratio-12.89
Taxes
In the past 12 months, Rhythm Pharmaceuticals has paid 346.00K in taxes.
Income Tax346.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Rhythm Pharmaceuticals EV to EBITDA ratio is -15.04, with an EV/FCF ratio of -31.45.
EV to Sales27.53
EV to EBITDA-15.04
EV to Free Cash Flow-31.45
EV to Operating Cash Flow-31.45
Balance Sheet
Rhythm Pharmaceuticals has $416.05M in cash and marketable securities with $151.00M in debt, giving a net cash position of $265.05M billion.
Cash & Marketable Securities$416.05M
Total Debt$151.00M
Net Cash$265.05M
Net Cash Per Share$3.97
Tangible Book Value Per Share$2.60
Margins
Gross margin is 89.40%, with operating margin of -204.04%, and net profit margin of -200.27%.
Gross Margin89.40%
Operating Margin-204.04%
Pretax Margin-200.00%
Net Profit Margin-200.27%
EBITDA Margin-182.97%
EBIT Margin-184.17%
Analyst Forecast
The average price target for Rhythm Pharmaceuticals is $124.45, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$124.45
Price Target Upside29.78% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast54.92%
EPS Growth Forecast28.47%